Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 10.12.2021 | 07:00

Record revenue for Carl Zeiss Meditec in fiscal year 2020/21

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Annual Results/Annual Report
10.12.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Record revenue for Carl Zeiss Meditec in fiscal year 2020/21
 
Major innovations launched in ophthalmic surgery and digitization
 

JENA, 10 December 2021

Carl Zeiss Meditec generated revenue of approximately €1,647m in fiscal year 2020/21 (prior year: €1,336m), corresponding to growth of +23.3% (adjusted for currency effects: +26.5%). Orders received increased even more significantly to approximately €1,731m (+29.1%, adjusted for currency effects: +32.6%). Earnings before interest and taxes (EBIT) increased disproportionately to approximately €374m (prior year: €178m). The EBIT margin was 22.7% (prior year: 13.3%).

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: "We remain on a clear growth trajectory; the economic effects of the pandemic are largely behind us. At the same time, we presented a number of major innovations to our customers at the end of the fiscal year - for example, in cataract surgery and digitization."

Both strategic business units contribute to growth

Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +26.8% in fiscal year 2020/21 (adjusted for currency effects: +29.8%), to €1,256m (prior year: €991m). In particular the business with recurring revenue from consumables, implants and services made a significant contribution to this growth. The recovery of revenue continued in the strategic business unit Microsurgery; there was an acceleration in the second half of the fiscal year in particular. Revenue increased by +13.4% (adjusted for currency effects: +17.1%) to €391m (prior year: €345m).

Clear double-digit percentage growth rates in all reporting regions

Revenue in the EMEA[1] region increased by +19.4% (adjusted for currency effects: +21.2%), to €433m (prior year: €362m). Once again, there was a positive trend in the markets of Germany, France and Southern Europe, and the UK.

Revenue in the Americas region increased by another +16.9% to €449m (prior year: €384m) due to the further acceleration of the U.S. business - adjusted for currency effects, revenue increased by +23.9%.

Once again, the APAC[2] region made the strongest contribution to growth. Revenue increased by 29.9% (adjusted for currency effects: +31.6%) to €765m (prior year: €589m). China and South Korea had the highest growth rates.

Significant increase in earnings year-on-year

The operating result (earnings before interest and taxes: EBIT) increased disproportionately in fiscal year 2020/21, to €374m (prior year: €178m). This was driven in particular by a favorable product mix and a high proportion of recurring revenue, as well as low selling and marketing expenses. The EBIT margin increased to 22.7% (prior year: 13.3%). Adjusted for special effects, this resulted in an increase to 23.0% (prior year: 13.8%). Earnings per share increased to €2.64 (prior year: €1.37).

Major innovations launched in ophthalmic surgery and digitization

A number of major innovations in ophthalmology were launched at the end of the fiscal year. The product range for cataract surgery was completed by a device for surgical lens extraction (ZEISS QUATERA 700) and a new intraocular lens (ZEISS CT LUCIA 621). A new generation of the femtosecond laser ZEISS VISUMAX 800 was launched for refractive laser surgery, which corrects ametropia in the eye. Products were also launched for digitization in ophthalmology.

Positive outlook for new fiscal year 2021/22

Due to the positive development of business and the high volume of orders, the Company is looking ahead to fiscal year 2021/22 with some optimism. Revenue is expected to grow at least to the same extent as the market. The EBIT margin in fiscal year 2021/22 is expected to be between 19-21%. In the medium term, the EBIT margin is expected to settle at a level sustainably above 20%, with the growing proportion of recurring revenue making a positive contribution. At the same time, there continues to be a need for significant strategic investments in research & development and sales & marketing.

Revenue by strategic business unit

All figures in €m 12 months 2020/21 12 months 2019/20 Change from prior year % Change from prior year %
(currency-adjusted)
Ophthalmic Devices 1,255.7 990.6 +26.8 +29.8
Microsurgery 391.1 344.8 +13.4 +17.1
Consolidated 1,646.8 1,335.5 +23.3 +26.5
 

Revenue by region

All figures in €m 12 months 2020/21 12 months 2019/20 Change from prior year % Change from prior year %
(currency-adjusted)
EMEA 432.6 362.4 +19.4 +21.2
Americas 448.9 384.0 +16.9 +23.9
APAC 765.3 589.0 +29.9 +31.6
Consolidated 1,646.8 1,335.5 +23.3 +26.5
 

Further information on our publication and the Analyst Conference Call on the results for fiscal year 2020/21 can be found at https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

 

Contact for investors and press

Sebastian Frericks
Head of Investor Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Europe/Middle East/Africa
[2] Asia/Pacific



10.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Landi Renzo: GBC-Interview mit CEO Christiano Musi

„Der Lani Renzo-Konzern ist ein globaler Akteur, der sich auf die Energiewende entlang der gesamten Wertschöpfungskette spezialisiert hat und darauf abzielt, ein weltweiter Referenzpunkt für RNG- und Wasserstoffanwendungen bei Green Mobility und Clean-Tech-Lösungen zu werden. Bis 2025 erwarten wir Umsatzzuwächse von 15% (CAGR) und ein zweistelliges EBITDA-Wachstum von 25% (CAGR), dank ansteigender Umsätze in Segmenten, die im Vergleich zu unserem traditionellen Markt für leichte Nutzfahrzeuge höhere Margen aufweisen."

Events im Fokus

Termine 2022

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

Aktueller Webcast

Nordex SE

Conference Call 15.08.2022 (Webcast)

15. August 2022

Aktuelle Research-Studie

A.S. Création Tapeten AG

Original-Research: A.S. Création Tapeten AG (von Montega AG): Kaufen

12. August 2022